The promising results obtained from pre-clinical models of AD demonstrate that cGAS and STING are unconventional but potentially druggable therapeutic targets covering different inflammatory mechanisms of action compared with current approaches to treat AD. This evidence concerns the gene STING1 and Alzheimer disease.